Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
House panel weighs $10,000 fiscal study for insurance coverage of biomarker testing; members question scope and longevity
Loading...
Summary
A strike‑all draft of S.154 would direct the Department of Financial Regulation and Agency of Human Services to estimate the cost of requiring insurers and Medicaid to cover biomarker testing; the draft includes a $10,000 appropriation for DFR, and lawmakers questioned how DFR/AHS would determine which tests to cost and whether the study could be quickly outdated.
A committee staff presenter described a strike‑all amendment to S.154 on April 14 that would require the Department of Financial Regulation (DFR) and the Agency of Human Services (AHS) to analyze the costs of requiring health insurers and Medicaid to cover biomarker testing that is supported by medical and scientific evidence. The draft includes a $10,000 appropriation to DFR in fiscal year 2027 for that analysis.
"It's asking them to come back with an estimated amount that insurance premiums would increase and what it would cost for Medicaid if Vermont were to enact legislation requiring health insurance coverage of biomarker testing," the presenter said. The amendment removes certain definitional language and directs DFR and AHS to report to the committee and relevant Senate committees.
Lawmakers pressed the presenter on procedural questions and the analysis scope. "How do you determine which biomarkers are included?" one member asked, noting that biomarker testing is not limited to a single disease and that tests and standards are evolving quickly. The presenter said DFR and AHS would identify the set or sets of biomarkers to cost as part of the analysis and that the Joint Fiscal Office (JFO) would produce an updated fiscal note.
Committee members voiced several concerns. One member said biomarker tests are already covered by Medicaid and commercial insurance when "medically necessary," and another questioned whether a $10,000 study is an effective use of DFR's resources given rapidly emerging technology: "Things are emerging so quickly. It could be a study that's obsolete in 5 years," the member said. Another member asked whether pharmaceutical interests motivated the effort, noting recent debate around Alzheimer’s medications and associated diagnostics.
The chair said he would not take a vote on S.154 at that time. The committee discussed the $10,000 fiscal line and whether DFR should absorb the cost from its existing budget, and staff said they would obtain an updated fiscal note from JFO and continue the conversation at markup.
No vote was taken on S.154 during the April 14 session; staff will return with updated fiscal information and further testimony at the committee's next scheduled markup.
